Recommendation of the President – Omvoh (mirikizumab)
On 6 August 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 84/2024 on the evaluation of the drug Omvoh (mirikizumab) under the drug program: “Treatment of patients with ulcerative colitis (UC) (ICD-10: K51)”